AI Article Synopsis
Article Abstract
The function of the p53 protein is impaired by the overexpression of its negative regulator murine double minute 2 protein (MDM2) and homologous protein MDMX. Disruption of the p53-MDM2/MDMX interaction to restore the transcriptional function of p53 is considered a promising strategy for cancer therapy. To design dual MDM2/MDMX inhibitors, the binding modes of MDM2 or MDMX with their inhibitors are elucidated. Several hot-spot residues of MDM2 or MDMX are identified by molecular dynamics simulations, alanine scanning and MM-GBSA calculations. Then, focusing on the interaction with hot-spot residues, two series of derivatives bearing 1,3-diketone and α-aminoketone scaffolds are designed and synthesized. Among these compounds, C16 is identified as the most potent compound with low micromolar binding affinities with MDM2 and MDMX. C16 also displays moderate antiproliferative activities against MDM2-overexpressing and MDMX-overexpressing cells, with IC values of 0.68 μM in HCT116 cells and 0.54 μM in SH-SY5Y cells. Furthermore, C16 inhibits cell migration and invasion, reactivates the function of p53, arrests the cell cycle and induces cellular apoptosis in HCT116 and SH-SY5Y cells. Collectively, C16 can be developed as a dual MDM2 and MDMX inhibitor for cancer therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejmech.2023.115282 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dysregulation of the p53 pathway provides a therapeutic target in aggressive pediatric sarcomas with stem-like traits.
Cell Oncol (Dordr)
December 2024
Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, 625 00, Czech Republic.
Purpose: Pediatric sarcomas are bone and soft tissue tumors that often exhibit high metastatic potential and refractory stem-like phenotypes, resulting in poor outcomes. Aggressive sarcomas frequently harbor a disrupted p53 pathway. However, whether pediatric sarcoma stemness is associated with abrogated p53 function and might be attenuated via p53 reactivation remains unclear.
View Article and Find Full Text PDFResurrecting p53 by an Artificial Nano-Protein for Potent Photodynamic Retinoblastoma Therapy.
Small
November 2024
Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
The treatment of retinoblastoma (RB), a formidable eye cancer that affects infants and children, is not only aimed at saving lives but at preserving ocular function, maintaining optimal visual acuity, and enhancing the overall quality of life. Photodynamic therapy has already been established as a secure and dependable therapeutic modality for the treatment of ocular diseases that effectively preserves ocular function; however, it fails to provide satisfactory outcomes against RB. To address this formidable challenge, groundbreaking advancement is aspired by delving into the genetic characteristics of RB, which initially involves the wild-type p53 pathway but is subsequently suppressed by MDM2 and MDMX.
View Article and Find Full Text PDFAn update patent review of MDM2-p53 interaction inhibitors (2019-2023).
Expert Opin Ther Pat
December 2024
Institute of Molecular and Industrial Biotechnology, Lodz University of Technology, Lodz, Poland.
Article Synopsis
- The p53 tumor suppressor protein is commonly disrupted in cancers through TP53 mutations or MDM2 overexpression, leading to interest in inhibitors that can release p53 for cancer therapy.
- The article reviews patents and patent applications from 2019 to 2023 for MDM2-p53 interaction inhibitors, categorizing newly discovered compounds into five groups based on their chemical structure.
- Despite two decades of research and various clinical evaluations, no MDM2-p53 inhibitors have been approved for market use yet, though over ten are still undergoing clinical trials, including some with promising FDA designations.
An Anti-Invasive Role for Mdmx through the RhoA GTPase under the Control of the NEDD8 Pathway.
Cells
September 2024
CRBM, Cell Biology Research Centre of Montpellier, Université de Montpellier, CNRS, 34293 Montpellier, France.
Article Synopsis
- * Research shows that Mdmx plays an anti-invasive role by stabilizing and activating the RhoA GTPase, especially in the context of NEDD8 pathway inhibitors during cell migration in Xenopus embryos.
- * The study identifies that while Mdmx promotes RhoA activation, prolonged inhibition of NEDDylation leads to Mdmx degradation by non-NEDDylated Culin4A and the Mdm2 E3-ligase, impacting its anti-invasive effects and hinting at its importance in the effectiveness of NEDD8 pathway inhibitors in
Rational design, synthesis, and biophysical characterization of a peptidic MDM2-MDM4 interaction inhibitor.
Bioorg Med Chem
November 2024
Dipartimento di Scienze Farmaceutiche, Università degli Studi di Perugia, Via del Liceo, 1, 06123 Perugia, Italy. Electronic address:
In recent years, the restoration of p53 physiological functions has become an attractive therapeutic approach to develop novel and efficacious cancer therapies. Among other mechanisms, the oncosuppressor protein p53 is functionally regulated by MDM2 through its E3 ligase function. MDM2 promotes p53 ubiquitination and degradation following homodimerization or heterodimerization with MDM4.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!